Celiac.com Sponsor (A1):

Celiac.com Sponsor (A1-m):

  • You've found your Celiac Tribe! Join our like-minded, private community and share your story, get encouragement and connect with others.


    • Sign In
    • Sign Up
  • Jefferson Adams

    Major Financing for HLA-Targeted Autoimmune Therapies Could Lead to New Celiac Treatments

    Jefferson Adams
    2 2
    Reviewed and edited by a celiac disease expert.

      IM Therapeutics announces $10 million in Series A financing to support its new HLA-targeted treatment approach that could lead to treatments for type-1 diabetes, celiac disease, and other autoimmune disorders.

    Image: CC BY 2.0--Magnus Manske
    Caption: Image: CC BY 2.0--Magnus Manske

    Celiac.com 10/23/2019 - Autoimmune therapy company ImmunoMolecular Therapeutics (IM Therapeutics) has received $10 million in Series A financing to support its new HLA-targeted treatment approach to autoimmune diseases, and to develop its lead HLA-targeted drug candidate for type 1 diabetes. 

    Founded by physician scientists at the University of Colorado's Barbara Davis Center for Diabetes, IM Therapeutic creates personalized therapies for autoimmune diseases.

    Celiac.com Sponsor (A12):

    Celiac.com Sponsor (A12-m):

    The company's research has shown that blocking certain high risk human leukocyte antigen (HLA) genes also blocks the subsequent autoimmune response, which offers a possible way to prevent autoimmune triggering in a number of autoimmune diseases.

    Based on that research, the company is creating personalized therapies against HLA targets in various autoimmune diseases, including type 1 diabetes and celiac disease. The company has clinically proven that treating patients based on HLA-DQ8 status can reduce the autoimmune response in type 1 diabetes. 

    With a technology platform that integrates computational chemistry, bioassays, and rational drug design, IM Therapeutics is developing a series of HLA targets for a number of autoimmune diseases.

    IM Therapeutics' personalized therapy approach to treating autoimmune disorders has proven effective in a Phase 1b human study of recently diagnosed type 1 diabetes patients who were positive for the HLA DQ8 variant. 

    The Company is moving forward on its lead oral drug, IMT-002, through IND development for type 1 diabetes, and expanding its therapeutic HLA blocking treatments to other targets of autoimmune disorders, including celiac disease.

    IM Therapeutics’ HLA is currently focused on HLA-DQ8 and DQ2 gene variants, which are known to greatly increase individual risk to both type 1 diabetes and celiac disease. 

    HLA-DQ8 is present in three out of five type 1 diabetes patients, and in one out of ten celiac disease patients. However, about 90% of celiac patients have DQ2, and nearly 100% of celiac patients have DQ2 and/or DQ8.

    “Our value has been clear since day one – getting to the root cause of autoimmunity with a targeted therapy approach and making an impact on diseases such as type 1 diabetes,” said Nandan Padukone, Ph.D., CEO of IM Therapeutics. 

    Read more at Businesswire.com

    2 2

    User Feedback

    Recommended Comments

    There are no comments to display.

    Join the conversation

    You are posting as a guest. If you have an account, sign in now to post with your account.
    Note: Your post will require moderator approval before it will be visible.

    Add a comment...

    ×   Pasted as rich text.   Restore formatting

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.

  • About Me

    Jefferson Adams is Celiac.com's senior writer and Digital Content Director. He earned his B.A. and M.F.A. at Arizona State University, and has authored more than 2,500 articles on celiac disease. His coursework includes studies in science, scientific methodology, biology, anatomy, medicine, logic, and advanced research. He previously served as SF Health News Examiner for Examiner.com, and devised health and medical content for Sharecare.com. Jefferson has spoken about celiac disease to the media, including an appearance on the KQED radio show Forum, and is the editor of the book "Cereal Killers" by Scott Adams and Ron Hoggan, Ed.D.

  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):

    Celiac.com Sponsors (A17-m):

  • Related Articles

    Jefferson Adams
    Celiac.com 05/30/2016 - People with HLA genes have the highest risk factor for developing autoimmune disorders. The vast majority of people with celiac disease carry the HLA DQA1*05 and DQB1*02 alleles, both of which encode the DQ2.5 molecule.
    A research team recently set out to examine the implications for anti-gluten T cell response of the preferential expression of HLA-DQ2.5 genes associated with celiac disease with respect to non-predisposing HLA genes. The research team included L Pisapia, A Camarca, S Picascia, V Bassi, P Barba, G Del Pozzo, and C Gianfrani. They are variously affiliated with the Institute of Protein Biochemistry-CNR, the Institute...

    Jefferson Adams
    Celiac.com 03/16/2017 - When screening arthritis patients for celiac disease, should HLA be done before serology? During the past decades, an accumulating evidence shows a dramatic rise in the frequency of autoimmune diseases, including rheumatoid arthritis and gastrointestinal conditions, such as celiac disease.
    HLA genes have been shown to be strongly associated with numerous autoimmune diseases, including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) and celiac disease. A team of researchers recently set out to assess the performance of celiac disease associated serology in face of a rheumatologic patient, when gluten enteropaty...

    Jefferson Adams
    Celiac.com 03/07/2019 - Researchers don’t have much good data on the distribution of the related alleles in the type 1 diabetes Iranian population. In an effort to generate better data, a team of researchers recently set out to assess the frequency of HLA DQ2 and DQ8 haplotypes in patients with type 1 diabetes, with and without celiac disease, and to compare them to the healthy population.
    The research team included Ali Moheb-Alian, Flora Forouzesh, Amir Sadeghia, Kamran Rostami, Elham Aghamohammadi, Mohammad Rostami-Nejad, Mostafa Rezaei-Tavirani, and Mohammad Reza Zali.
    The team looked at 70 type 1 diabetes patients who did not have cel...

    Jefferson Adams
    Celiac.com 07/29/2019 - Gluten and related prolamines trigger celiac disease in people who are genetically susceptible. The role of HLA-DQ genotypes is not well understood. A team of researchers recently set out to investigate the influence of HLA-DQ genotypes in clinical, serological and histological features related to celiac disease.
    The research team included Eva Martínez-Ojinaga, Marta Fernández-Prieto, Manuel Molina, Isabel Polanco, Elena Urcelay and Concepción Núñez. They are variously affiliated with the Servicio de Gastroenterología y Nutrición Pediátrica, Hospital Universitario La Paz in Madrid, Spain; and the Laboratorio de investigación en Gen...